Duan Jiachen, Jin Mengyuan, Qiao Baoping
Department of Urology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, Henan 450052, People's Republic of China.
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Transl Oncol. 2022 Aug;22:101453. doi: 10.1016/j.tranon.2022.101453. Epub 2022 May 20.
Clear cell renal cell carcinoma (ccRCC) is the most common type of RCC and is associated with poor survival. However, the mechanisms underlying its development have not been thoroughly investigated. Semaphorin 6D (SEMA6D) is differentially expressed in various cancers, including lung adenocarcinoma and colorectal cancer. However, the role and mechanism of SEMA6D in ccRCC remain unexplored.
We obtained 25 pairs of ccRCC tissue samples and 57 urine samples from patients with ccRCC and 52 urine samples from healthy volunteers. We performed RNA sequencing and compared the results with data from The Cancer Genome Atlas database to identify our gene of interest, SEMA6D. To verify the differential expression of SEMA6D, we used real-time quantitative polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay. Finally, we conducted in vitro proliferation, migration and invasion experiments.
SEMA6D expression was significantly lower in ccRCC tissue compared to that in normal tissue. Comparative analysis of our results with data from online databases revealed that the expression level of SEMA6D in ccRCC tissue correlated with the clinical stage and pathological grade of ccRCC. Furthermore, higher SEMA6D expression was associated with improved quality of life of patients with ccRCC. In addition, the diagnostic value of SEMA6D was confirmed using data from two Gene Expression Omnibus ccRCC databases. The results showed that SEMA6D can be used as a predictor for ccRCC diagnosis, with an area under the curve of 0.9642.
SEMA6D may serve as a diagnostic and prognostic biomarker for ccRCC.
透明细胞肾细胞癌（ccRCC）是肾细胞癌最常见的类型，且与较差的生存率相关。然而，其发展的潜在机制尚未得到充分研究。信号素6D（SEMA6D）在包括肺腺癌和结直肠癌在内的各种癌症中存在差异表达。然而，SEMA6D在ccRCC中的作用和机制仍未被探索。
我们获取了25对ccRCC组织样本以及来自ccRCC患者的57份尿液样本和来自健康志愿者的52份尿液样本。我们进行了RNA测序，并将结果与癌症基因组图谱数据库的数据进行比较，以确定我们感兴趣的基因SEMA6D。为了验证SEMA6D的差异表达，我们使用了实时定量聚合酶链反应、免疫组织化学和酶联免疫吸附测定。最后，我们进行了体外增殖、迁移和侵袭实验。
与正常组织相比，ccRCC组织中SEMA6D的表达显著降低。将我们的结果与在线数据库的数据进行比较分析发现，ccRCC组织中SEMA6D的表达水平与ccRCC的临床分期和病理分级相关。此外，较高的SEMA6D表达与ccRCC患者生活质量的改善相关。此外，使用来自两个基因表达综合ccRCC数据库的数据证实了SEMA6D的诊断价值。结果表明，SEMA6D可作为ccRCC诊断的预测指标，曲线下面积为0.9642。
SEMA6D可能作为ccRCC的诊断和预后生物标志物。
